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Asthma is a clinical disorder commonly characterized by chronic eosinophilic
inflammation, remodeling and hyper responsiveness of the airways. However, the kinases
like Phosphoinositide 3 kinase (PI3K) and Janus kinase 3 (JAK3) are involved in mast cell
proliferation, activation, recruitment, migration, and prolonged survival of inflammatory
cells. The present study was designed to evaluate the in-vivo comparative effects of
two kinase inhibitors on airway inflammation and airway remodeling in acute and chronic
models of asthma. Mice were sensitized twice intra-peritoneally and then challenged by
inhalation with ovalbumin (OVA). They developed an extensive inflammatory response,
goblet cell hyperplasia, collagen deposition, airway smooth muscle thickening similar to
pathologies observed in human asthma. The effects of PI3K inhibitor (30 mg/kg, p.o),
JAK3 inhibitor (30 mg/kg, p.o) and Dexamethasone (0.3 mg/kg) on airway inflammation
and remodeling in OVA sensitized/challenged BALB/c mice were evaluated. Twenty-four
hours after the final antigen challenge, bronchoalveolar lavage (BAL) and histological
examinations were carried out. It was observed that kinase inhibitors significantly reduced
airway inflammation as evidenced by the decrease in pro inflammatory cytokines in
BALF and lung homogenate and inflammatory cell count in sensitized mice after allergen
challenge. Lung histological analysis showed increased infiltration of inflammatory cells,
hyperplasia of goblet cells and the collagen deposition, which were significantly reduced
with kinase inhibitor. In conclusion, our data suggest that PI3K and JAK3 inhibitors
showed promising alternative therapeutic activity in asthma, which might significantly
counteract the airway inflammation in patients with allergic asthma.
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INTRODUCTION
Asthma is a complex disease characterized clinically by reversible bronchial obstruction
(Deshpande et al., 2010) and airway hyper-responsiveness (AHR) (Brannan and Lougheed, 2012).
Asthma affects more than 334 million people worldwide (GAR, 2014). Post-mortem and lung
biopsy studies have revealed pulmonary infiltration of eosinophils, lymphocytes, macrophages,
and mast cells in asthmatics. In addition, structural changes in the cellular and extracellular
components of the asthmatic bronchi, such as airway wall thickening, subepithelial fibrosis, goblet
cell hyperplasia, myofibroblast hyperplasia, airway smooth muscle cell hyperplasia, hypertrophy,
and epithelial hypertrophy collectively which are known as airway remodeling have been reported
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(Szefler and Dakhama, 2011). Allergic asthma is a common
inflammatory disease of the airway, and long-term therapy is
aimed to counteract the episodes of bronchospasm and reducing
allergic inflammation (Montuschi and Barnes, 2011). Although
such strategies are successful, they neither cure nor prevent
asthma and in some cases, have not prevented the disease from
progressing (Colice et al., 2012). Therefore, new therapeutic
strategies must be identified to overcome from limited drug
availability (Holgate et al., 2008). Thus, there is an unmet
need to develop new targeted therapy with improved efficacy
and safety profile. Generally, targeting a single cell may not
be an ideal approach for the treatment of asthma because
of the redundant and overlapping responses of inflammatory
cells. Therefore, a more plausible approach must be considered
to target the common upstream pathway that controls the
pathogenic responses of multiple inflammatory components.
Kinase signaling cascades represent an attractive target
for anti-inflammatory therapy for asthma. Specific inhibitors
reduce activity of critical kinase signaling cascade, which might
produce sufficient relief to patients suffering from allergic airway
inflammation. Among these Janus kinase 3 (JAK3) has been
reported to regulate macrophage expression by inducible nitric
oxide synthase (iNOS) and nitric oxide production (Mullen and
Gonzalez-Perez, 2016), mast cell proliferation and functioning
(Han et al., 2014). JAK3 is also involved in immunoglobin-
E (IgE) class switching, mediating responses of dendritic cells,
macrophages and non-hematopoietic lineage cells in asthma
(Malaviya and Laskin, 2010; Walford and Doherty, 2013). JAK3
inhibitors act as potent inhibitors of IgE receptor-mediated 5-
lipooxygenase (LO) dependent leukotriene synthesis in mast
cells. JAK3 inhibitor indirectly inhibits the enzymatic activity
of 5-LO, by preventing the antigen/IgE dependent translocation
of 5-LO from nucleoplasm/cytoplasm to nuclear envelope (Liao
et al., 2013). Phosphoinositide 3 kinase (PI3K) inhibitors revealed
their anti-inflammatory effects by suppressing antigen-induced
airway inflammatory cell infiltration, production of interleukin-
4 (IL-4), interleukin-5 (IL-5), interleukin-13 (IL-13), eosinophil
cationic protein, and eotaxin in BAL fluid, goblet cell hyperplasia,
and airway hyper responsiveness (Stark et al., 2015). Hence this
study has been carried out to investigate the comparitive role
of PI3 Kinase and Janus Associated Kinase 3 inhibitors as novel
therapies for the treatment of asthma.
MATERIALS AND METHODS
Experimental Animal
Seven- to eight- weeks- old BALB/c mice were purchased and
maintained in the specific pathogen-free animal facility at Zydus
Research Centre (Gujarat, India). For the acute study, the mice
(n = 6 per group) were then sensitized intraperitoneally on
day 0 with 2%OVA (Qualigens fine chemicals) and 1% alum
in normal saline (0.2ml per mice) and 5% OVA and 1% alum
on day 7. The mice were periodically challenged with 5% OVA
for 30min through nebulizer from days 14 to 16 in an acrylic
Abbreviations: PI3K, Phosphoinositide 3 kinase; JAK3, Janus kinase 3; OVA,
Ovalbumin; iNOS, Inducible nitric oxide synthase.
chamber. On day 17 (24 h after the final OVA challenge) the mice
were sacrificed. In the chronic study, mice were intraperitoneally
injected with 2% OVA and 1% of Alum on day 0, followed by
5%OVA and 1% alum on day 14. The same mice were challenged
with 5%OVA from days 21 to 30 (Donaldson et al., 2013). On day
31, the mice were sacrificed and BAL and lungs were collected.
As a negative control, saline was used instead of OVA during
the sensitization and challenge phase, for both acute and chronic
study. All animal experimental protocols were approved by the
Zydus Animal Ethics Committee.
Treatment
The mice were treated with PI3K inhibitor (INK654 molecule
obtained from Intellikine Inc, 30mg/kg), JAK3 inhibitor
(Tofacitinib, Pifzer, 30mg/kg) and dexamethasone (0.3mg/kg).
The drugs were prepared in 0.5% carboxymethylcellulose and
administered orally 1 h prior to OVA challenge–from days 14 to
16 (3 days) and days 21 to 30 (10 days) for acute and chronic
study, respectively. Control mice received vehicle orally. All
drugs were freshly prepared. The inflammatory cell counts and
cytokines levels weremeasured 24 h after the final OVA challenge.
Cytokines were measured in BAL and lung homogenate by using
ELISA reagent kit.
Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) was immediately performed after
24 h of final OVA challenge. Mice were sacrificed by spinal
dislocation. The lungs were lavaged insitu via tracheal cannula
with ice-cold heparinised saline (0.5ml X 4) followed by
centrifugation of BALF (8000 rpm for 10min at 4◦C). The
supernatant was stored at −80◦C for cytokines assay. The pellets
were resuspended in saline and the total cell and differential cell
counts were performed by using the cell counter instrument.
The lungs were collected and sliced: one portion to study
lung histopathology and second portion for cytokines and
hydroxyproline level estimation.
ELISA Test
Quantification of IL-5, IL-6, TNF-alpha, IL-2, and IFN-gamma in
BALF and lung homogenate were carried out by using Enzyme-
linked immunosorbent assay (ELISA) kit (B.D. Biosciences
pharmingen, Bedford, USA), according to the manufacturers
protocol. The detection limits for mouse IL-2 and IFN-gamma
were 3.2–200 pg/ml whereas 15.6–1000 pg/ml for mouse IL-5,
IL-6 and TNF-alpha.
Histological Examination of Murine Lung
Tissue
Paraffin-embedded lung tissue was sectioned into 4µm and
dewaxed with xylene. The sections were then stained with
hematoxylin-eosinto study cell infiltration, Periodic acid Schiff
stain to examine mucus secretion, & Sirius red staining
for collagen deposition. Olympus Provis AX70 microscope
(Olympus, Lake Success, NY) equipped with a spot RT color
digital camera (Diagnostic Instruments, Sterling Heights, MI)
were applied to capture the image.
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FIGURE 1 | Effect of treatment on inflammatory cells count in BAL fluid on exposure to kinase inhibitors (30mg/kg). (A–D) the cell counts in acute model
of asthma after 3 days of treatment. (E–H) the cell counts in chronic model of asthma after 10 days of treatment. Data were analyzed by one-way ANOVA followed by
Dunnett’s multiple comparisons test. Values were expressed as Mean ± S.E.M. (n = 6). Statistical significance was assessed as **p < 0.01 vs. OVA-treated group and
#p < 0.01 vs. control mice group.
Quantification of Hydroxyproline Level
Hydroxyproline is a collagen deposition marker that can
be measured in lung homogenate and is indicative of
airway remodeling. Deposition of collagen in lungs is
indicative of lung fibrosis (Limjunyawong et al., 2014;
Srivastava et al., 2016). Samples were treated with alkali for
hydrolysis and oxidized with chloramine T to form pyrrole.
The addition of Ehrlich’s reagent resulted into formation
of chromophore that was measured at a bandwidth of
550 nm.
Statistical Analysis
All data were expressed as means± standard error mean (S.E.M).
Total cell counts, differential cell counts, and cytokines in BALF
and lung homogenate were analyzed by one-way analysis of
variance (ANOVA). Each test was followed by the Dunnets
Frontiers in Pharmacology | www.frontiersin.org 3 February 2017 | Volume 8 | Article 82
Wagh et al. Kinase Inhibitors in Asthma
FIGURE 2 | Effect of treatment on cytokine levels in acute and chronic model of asthma. (A–C) the level of cytokines (TNF-α, IL-5, and IL-6) were measured
in BAL fluid in acute model mice. In chronic model mice, the TNF-α (D) from lung homogenate and IL-5 and IL-6 (E,F) levels from BAL fluid were determined after 10
days of treatment. Data were analyzed by one-way ANOVA followed by Dunnett’s multiple comparisons test. Values were expressed as Mean ± S.E.M. (n = 6).
Statistical significance was assessed as **p < 0.01, *p < 0.05 vs. OVA-treated group and #p < 0.01 vs. control group.
multiple comparison. P-values less than 0.05 (p < 0.05) were
considered statistically significant.
RESULTS
Effect of Kinase Inhibitors on Inflammatory
Cell Recruitment in BALF
OVA-treated mice showed elevation of total inflammatory
cells in BALF. On treatment with PI3K and JAK3 inhibitors
orally (30 mg/kg), the inflammatory cell counts, such as
basophils, neutrophils, macrophages and lymphocytes were
reduced to almost normal and p-value was statistically
significant in acute (Figures 1A–D; Supplementary Figure
1C and Supplementary Table 1) and chronic model of asthma
(Figures 1E–H; Supplementary Figure 1D and Supplementary
Table 4), except eosinophil level in acute model (Supplementary
Figure 1A).
However, in chronicmodel the level of eosinophil was reduced
by 4-fold (Supplementary Figure 1B) with PI3K inhibitor, which
indicates oral dosing suppresses eosinophilic inflammation in
chronic allergic airway inflammation.
Effects of Kinase Inhibitors on Cytokines in
BALF and Lung Homogenate in Acute and
Chronic Model of Asthma
In acute model of asthma, the levels of TNF-α (p < 0.05) and
IL-6 (p < 0.01) in BALF obtained from OVA-treated mice were
higher as compared to control mice. Treatments decreased the
levels of TNF-α and IL-6 in BALF (Figures 2A–C; Supplementary
Table 2) and lung homogenate (Supplementary Figures 2A,C
and Supplementary Table 3) compared to OVA-treated mice.
Levels of IFN-gamma and IL-2 (Th-1 cell mediated cytokines)
were lower in OVA than control mice, but the treatments were
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ineffective in increasing the level of protective cytokines in both
BALF (Supplementary Figures 3A,B and Supplementary Table
2) and lung homogenate (Supplementary Figures 3C,D and
Supplementary Table 3). IL-5 (major cytokine responsible for
eosinophilic infiltration in asthma) was found to be higher in
BALF and lung homogenate of OVA-treated mice as compared
to control mice. However, the treatments were ineffective in
reducing the IL-5 level in BALF (Figure 2B; Supplementary
Table 2) and lung homogenate (Supplementary Figure 2B and
Supplementary Table 3).
In asthma model of chronic allergic airway inflammation,
the TNF-α (p < 0.05) and IL-6 (p < 0.01)levels were reduced
in BALF and lung homogenate on treatment with kinase
inhibitor (Figures 2D–F; Supplementary Figures 2D–F and
Supplementary Tables 5, 6). IL-5 level was reduced with a p-value
of <0.01 in BALF (Figure 2E; Supplementary Table 5) and
lung homogenate (Supplementary Figure 2E and Supplementary
Table 6). The protective cytokines (IFN-gamma and IL-2)
were not significantly recovered by treatments as observed in
BALF (Supplementary Figures 3E,F and Supplementary Table
5) and lung homogenate (Supplementary Figures 3G,H and
Supplementary Table 6).
Effects of Kinase Inhibitors on
Hydroxyproline Levels in Lung
Homogenate
In OVA–treated mice the levels of hydroxyproline was increased
as compared to control mice. However, on treatment with
PI3K inhibitor, the level of hydroxyproline was reduced in lung
homogenate (Figure 3).
Effects of Kinase Inhibitors on
Inflammatory Cells and Mucus Production
and Collagen Deposition
On day 31, the lung tissues were histologically examined. OVA—
treated mice were dosed with PI3K inhibitor (30mg/kg) and
dexamethasone (0.3mg/kg). All the subsequent samples of lung
tissues were stored in paraffin to perform the histological analysis.
In control mice no inflammatory responses were observed
(Figure 4A-i), whereas OVA-treated mice showed extensive
infiltration of inflammatory cells around airways and blood
vessels (Figure 4A-ii) on hematoxylin and eosin staining lung
tissue. The majority of the infiltrated inflammatory cells were
eosinophils. On administration of PI3K inhibitor (30 mg/kg; p.o)
reduction in inflammatory cells was observed in peribronchial
and perivascular region in comparison with OVA-treated mice
(Figure 4A-iii). On periodic acid–Schiff staining the presence
of goblet cells were seen in OVA sensitized mice. On treatment
with kinase inhibitor (30 mg/kg) the hyperplasia of goblet cells
were reduced and lower the production of mucus (Figure 4B).
Increased airway collagen deposition, a typical feature of airway
remodeling in chronic asthma, was assessed peribronchial
(Grainge et al., 2011). Sirius red staining indicated the excessive
deposition of collagen in the lungs of OVA-treated mice which
were reduced in treated mice (Figure 4C).
DISCUSSION
The present study was proposed to investigate the effect of
PI3K and JAK3 inhibitors on airway inflammation characterized
by infiltration of inflammatory cells, differential release of
cytokines and airway remodeling in acute and chronic model
of OVA sensitized mice (Supplementary Figure 4). In this
study, we observed significant elevation of inflammatory
cells i.e., eosinophil, basophils, neutrophils, macrophages, and
lymphocytes in BALF. Our findings are in accordance with earlier
findings (Grommes and Soehnlein, 2011; Possa et al., 2013).
Thus, the ability to control leukocyte infiltration into lungs is
viewed as a key factor in regulating disease severity (Lin et al.,
2013).
In acute model of asthma, PI3K and JAK3 inhibitors, and
dexamethasone were found effective in inhibiting infiltration
FIGURE 3 | The effect of different treatments on hydroxyproline levels in lung homogenate after 10 days of treatment. Data were analyzed by one-way
ANOVA followed by Dunnett’s multiple comparisons test. Values were expressed as Mean ± S.E.M. (n = 6). Statistical significance was assessed as **p < 0.01, *p <
0.05 vs. OVA-treatedgroup and #p < 0.01 vs. control mice.
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FIGURE 4 | Histological features of lung tissue sectioned at 5 µm was
assessed after staining with (A) Hematoxylin and eosin staining:(i)control
mice, (ii) OVA-treated, (iii) PI3Ki (30mg/kg, p.o), and (iv) Dexamethasone
(0.3mg/kg, p.o), (B) Periodic acid–Schiff staining:(i)control mice, (ii)
OVA-treated, (iii) PI3Ki (30mg/kg, p.o), and (iv) Dexamethasone (0.3mg/kg,
p.o) and (C) Sirius red staining:(i) control mice(ii) OVA-treated, (iii) PI3Ki
(30mg/kg, p.o) and (iv) Dexamethasone (0.3mg/kg, p.o). The arrow indicates
the infiltration and mucus secretion. All magnifications were performed at
resolution of 40x.
of basophils, macrophages, neutrophils, and lymphocytes into
bronchoalveolar compartment. In our study we observed
increase in basophils infiltration unexpectedly, however these
were also attenuated by the treatment. Kinase inhibitors showed
dominant inhibitory activity over dexamethasone. JAK3 inhibitor
was found highly effective in reducing the neutrophils infiltration
as compared to PI3K inhibitor and dexamethasone. However,
kinase inhibitors were not effective in inhibiting the eosinophil
count, while dexamethasone was found effective. TNF-alpha is
a key regulator of pro-inflammatory cytokine and activator of
inflammatory cells, which is increased in OVA exposed mice
(Zhou et al., 2015). Our results showed kinase inhibitors were
effective in inhibiting TNF-alpha in BALF.
Asthma is a Th-2 cell mediated disease, the elevated levels
of IL-5 and IL-6 were seen in OVA-treated mice (Deo et al.,
2010). In the present study, the level of IL-6 was decreased
significantly but not IL-5 in BALF and lung homogenate with
kinase inhibitors. Whereas, dexamethasone significantly reduced
the IL-5 levels post OVA challenge. Therefore, we observed a
clear correlation between cytokine IL-5 level and eosinophil
count. IFN-gamma and IL-2 are produced by Th-1 cells which
act as a protective mechanism in asthma and their levels were
lowered in OVA sensitized mice (Hall and Agrawal, 2014). In
this study, the levels of IFN-gamma and IL-2 were restored to
normal with JAK3 inhibitor. Level of hydroxyproline was also
measured as a biochemical marker of collagen deposition in
the lungs (Limjunyawong et al., 2014; Srivastava et al., 2016).
An increased level of hydroxyproline in OVA-treated mice was
observed, indicating collagen deposition and airway remodeling.
However, PI3K inhibitor was found effective in reducing the
levels of hydroxyproline in acute model of asthma. From the
acute model, we found an overall pronounced effect of JAK3
inhibitor, which is comparable to the first-line therapy drug
dexamethasone.
In chronic model of asthma, the PI3K inhibitor was effective
in reducing the inflammatory cell count as compared to
dexamethasone. Until now, it is reported that the decrease in
eosinophil in BALF was correlated with attenuation of asthma
symptoms in animal models (Asano et al., 2010). But many
clinical studies have also documented a correlation between
pulmonary eosinophilia and asthma, and the degree of eosinophil
in BALF correlates with disease severity (Ando et al., 2016).
Thus, pulmonary eosinophilia has been closely related to asthma
symptoms. The suppression of pulmonary eosinophilia by PI3K
inhibitor in a chronic model could be explained by the inhibition
of both differentiation andmigration of eosinophil. IL-5 critically
regulates expression of genes that are involved in proliferation,
cell survival and maturation of eosinophil (Schwartz et al., 2015).
TNF-α may also function as a pro-inflammatory cytokine that
causes differentiation and migration of eosinophils (Lin et al.,
2013) by recruiting IL-5. Thus, we understand PI3K inhibitor
reduces the eosinophils in BALF through suppression of IL-5
cytokines. And our studies suggest that IL-5 is more critical in
regulating eosinophils than TNF-alpha.
IFN-gamma and IL-2 levels were significantly increased in
BALF with Dexamethasone, but not with PI3K inhibitor in
asthma. On treatment with PI3K inhibitor there was decrease in
IL-6 level in OVA sensitized mice. In chronic model of asthma,
the PI3K inhibitor was effective in controlling airway remodeling
as evident by suppressed hydroxyproline level. Histopathology
study showed increased infiltration of inflammatory cells, goblet
cell hyperplasia, smooth muscle cell hypertrophy and collagen
deposition in the OVA-treated mice, which was reduced with
PI3K inhibitor. Moreover, the kinase inhibitors were effective
in suppressing inflammation and remodeling with no specific
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side-effects being observed in our study. Recently DP2 receptor
antagonists have entered clinical trials for asthma however are
faced with challenge to develop once daily treatment with more
clinical potency and require further in depth research for use in
severe uncontrolled asthma and in pediatric patients with asthma
(Santini et al., 2016).
Thus, it was observed that PI3K inhibitor efficiently treats
the lung inflammation by inhibiting cell count and cytokine
levels. We could not test the JAK3 inhibitor on chronic
model in the present study. Recent findings have suggested
that selective blocking of bradykinin B1 receptor may be an
additional therapeutic strategy for the treatment of allergic airway
inflammation (El-Kady et al., 2016). In summary, asthmatic
models of mice were effectively treated with kinase inhibitor and
this could become a closest option for treating allergic asthma.
CONCLUSION
In conclusion, kinase inhibitors were able to control the airway
inflammation characteristic of bronchial asthma in a murine
model of allergic asthma. New kinase inhibitors may yield
opportunities for the development of novel therapeutics to treat
severe asthma.
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